

ILUVIEN could preserve your vision longer with fewer injections.

#### INDICATION

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

#### **IMPORTANT SAFETY INFORMATION**

- Do not use ILUVIEN if you have or think you might have an infection in or around the eye.
- ILUVIEN should not be used if you have glaucoma with a cup to disc ratio of greater than 0.8.

# **ILUVIEN® Patient Journey**



#### 1. Evaluation: Are you a candidate?

You may be a candidate for ILUVIEN if you have been diagnosed with diabetic macular edema (DME).

ILUVIEN is indicated for patients who have been treated with corticosteroids before and did not have a significant rise in eye pressure. Based on clinical trials, ILUVIEN has been proven to be safe and effective in the treatment of DME for up to 36 months with a single injection.

Your eye doctor will perform a detailed evaluation to assess your condition and determine if you are a candidate for ILUVIEN.

- Corticosteroids may increase secondary eye infections due to bacteria, fungi, or viruses. Let your doctor know if you have a history of herpes viral infections of the eye.
- If the posterior capsule of the lens of your eye is missing or torn, the ILUVIEN implant may move to the front chamber of the eye.
- The most common side effects reported in patients with diabetic macular edema who were treated corticosteroids, including ILUVIEN, include cataracts (ILUVIEN 82%; sham 50%) and increased eye pressure (ILUVIEN 34%; sham 10%).
- This safety information is not comprehensive.
   For additional safety information, please talk to your doctor and see the full Prescribing Information for ILUVIEN at iluvien.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

## **Important Safety Information**

#### **INDICATION**

ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

#### **IMPORTANT SAFETY INFORMATION**

- Do not use ILUVIEN if you have or think you might have an infection in or around the eye.
- ILUVIEN should not be used if you have advanced glaucoma with a cup to disc ratio of greater than 0.8.
- You should not use ILUVIEN if you have a hypersensitivity to any components of ILUVIEN.
- Injections into the vitreous in the eye are associated with a serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, glaucoma, and retinal detachments. Your eye doctor should monitor you regularly after the injection.

#### 2. Insurance Benefit Investigation

Your retina specialist can submit a benefits investigation with your insurance to evaluate what amount your insurance will pay and the cost to you. If you are unable to pay the amount your insurance does not cover, there are several options to supplement your existing insurance.

# For more information visit ILUVIEN.com

#### **IMPORTANT SAFETY INFORMATION** (continued)

- You should not use ILUVIEN if you have a hypersensitivity to any components of this product.
- Injections into the vitreous in the eye are associated with a serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, glaucoma, and retinal detachments. Your eye doctor should monitor you regularly after the injection.

## **ILUVIEN® Patient Journey**

#### 3. ILUVIEN Injection

A single ILUVIEN is administered by a retina specialist during an in-office procedure. Prior to the procedure, your eye is cleaned and numbing solution applied. The ILUVIEN implant is injected into the eye. As it is being injected, you may feel some pressure in your eye.

#### 4. Follow-up

Your doctor will monitor your eye after the injection for possible side effects including development of cataracts, eye infection (endophthalmitis), increased eye pressure, glaucoma, and retinal detachments.

#### 5. Life with ILUVIEN

Many patients may experience sustained or improved vision, reduction in retinal edema, and significantly fewer eye injections after receiving ILUVIEN.

For more information visit ILUVIEN.com

# Independent Financial Assistance Foundations

You always have options in life. That includes paying for appropriate DME treatment. Independent financial assistance foundations are independent entities that provide financial assistance for patients insured by a government payer.

Contact AccessPlus today to learn more. Call 1-844-445-8843 (option 3)

For more information regarding financial assistance, visit iluvien.com/ support/financial-assistance/

#### **IMPORTANT SAFETY INFORMATION** (continued)

 The most common side effects reported in patients with diabetic macular edema who were treated with ILUVIEN include cataracts (ILUVIEN 82%; sham 50%) and increased eye pressure (ILUVIEN 34%; sham 10%).

#### **Financial Assistance**

#### ILUVIEN® AccessPlus Financial Assistance Services

If your eye doctor prescribes ILUVIEN, AccessPlus Financial Assistance Services may be able to help find options to assist you with your out-of-pocket costs for patients with or without insurance.

#### **ILUVIEN CoPay Program**

The ILUVIEN CoPay Program provides copay assistance for eligible, commercially-insured patients with out-of-pocket costs that exceed \$25.

You or your eye doctor can contact AccessPlus and choose option 3 when calling 1-844-445-8843.

#### **ILUVIEN Patient Assistance Program**

The ILUVIEN Patient Assistance Program can provide FREE treatment for qualified uninsured and rendered uninsured patients.

To apply for the Patient Assistance Program, complete the ILUVIEN Patient Assistance Program application with your eye doctor. If you are determined eligible, you and your eye doctor will receive an approval letter indicating that you may proceed with scheduling your injection appointment.

# ILUVIEN is the only option designed for continuous treatment of DME for up to 36 months.



#### **IMPORTANT SAFETY INFORMATION** (continued)

 Corticosteroids may increase secondary eye infections due to bacteria, fungi, or viruses. Let your doctor know if you have a history of herpes viral infections of the eye.

## **Questions to ask your doctor**

- **1.** How does diabetes affect diabetic macular edema (DME)?
- **2.** Are there steps I can take to help slow the progression of DME?
- **3.** How does recurring DME affect my vision?
- **4.** What are my options for treating DME and improving my vision?
- **5.** I have had diabetes for \_\_\_\_\_ year(s). Will this affect DME treatment types available to me?
- **6.** How can I reduce the number of eye injections I currently receive?
- 7. How does ILUVIEN work?
- **8.** Can I still get ILUVIEN even though I have another eye condition or prior eye surgery?
- **9.** What is the procedure for administering ILUVIEN?
- **10.** What type of payment or insurance coverage is available for ILUVIEN?
- **11.** What are the risks and possible side effects associated with ILUVIEN?
- **12.** What is my follow-up plan after an ILUVIEN injection?

For more information visit ILUVIEN.com

## about ILUVIEN®



#### **IMPORTANT SAFETY INFORMATION** (continued)

 If the posterior capsule of the lens of your eye is missing or torn, the ILUVIEN implant may move to the front chamber of the eye.



Many patients experience improved vision, reduction in retinal edema, and significantly fewer eye injections after ILUVIEN.



Ask your doctor about ILUVIEN and how one injection can continuously treat DME for up to 36 months.



Visit ILUVIEN.com to learn more about **the patient journey** or to watch patients describe their journey with ILUVIEN. Use your mobile device to scan the QR code.

Please see Important Safety Information throughout, on page 10, and in the enclosed full Prescribing Information.



ILUVIEN is a registered trademark of Alimera Sciences, Inc.
Copyright © 2022 Alimera Sciences, Inc. All rights reserved.
1-844-445-8843. Printed in USA. US-ILV-MMM-0031-04. 01/2022